Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Biomedical Research, Science, & Technology

Reports

Displaying 1 - 10 of 251. 10 per page. Page 1.

Advanced Search
ASPE Issue Brief

Novel Antimicrobial Drug Development and Access: U.S. Government Support and Opportunities

The pipeline and commercial market for novel antimicrobial drugs is insufficient to address current and future patient needs or mitigate the loss of effective treatments as antimicrobial resistance spreads. The U.S. Government implements a range of efforts to ensure sustainable availability of antimicrobial treatments, supporting research, product development, and appropriate use.
Report

Health Care Workforce: Key Issues, Challenges, and the Path Forward

This report outlines the major issues faced by the U.S. health care workforce. It addresses medical, dental and behavioral health components of the workforce as well as direct care workers. The report also describes opportunities for progress to address these issues and existing activities supported by the Department to address these issues.
ASPE Issue Brief

Participant Diversity by Race, Ethnicity, and Sex in Rare Disease Clinical Trials: A Case Study of Eight Rare Cancers

Rare cancer clinical trials appear to enroll less diverse participants than clinical trials more broadly and therefore may require additional considerations or unique solutions to diversify participant recruitment. These differences persisted within both NIH and non-NIH funded trials.
Report

Drug Development

The cost of bringing a medical product to the U.S. market has been increasing and clinical trials constitute a large portion of these costs. In drug development, the clinical phase lasts an average of around 95 months compared to 31 months for the non-clinical phase and accounts for 69 percent of overall R&D costs (DiMasi, et al., 2016).
Case Study

Elevating Prevention and Promotion Efforts in Early Childhood Mental Health: A Case Study Series Page

This series of five case studies describe evidence-based, innovative, and exemplary practices that support positive mental health for children. The case studies in five organizations highlight key elements of prevention and promotion efforts in early childhood mental health, as well as the contextual factors that support implementation.Available Reports:
Research Brief

Elevating Prevention and Promotion in Early Childhood Mental Health

Efforts to promote positive mental health and prevent the onset of mental health difficulties are crucial for supporting healthy early childhood social-emotional development and well-being.
Research Summary

FDA Breakthrough Therapy Designation Reduced Late-Stage Drug Development Time

This landing page presents the abstract of a paper published in Health Affairs. The full text of the article is available at: https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2023.00837.
Report

National Action Plan for Combating Antibiotic-Resistant Bacteria Progress Report: Fiscal Year 2022

The evolution of pathogens to resist the drugs used to treat infections is an ongoing threat to public health, animal health, food production, and national security. Globally, a recent analysis estimated that 1.2 million deaths were caused by antibiotic-resistant (AR) bacteria in 2019, making this threat a leading cause of death for people of all ages worldwide.
ASPE Issue Brief

Barriers and Opportunities for Improving Interstate Licensure Portability for Behavioral Health Practitioners: Technical Expert Panel Findings Issue Brief

In October 2022, ASPE convened a virtual technical expert panel (TEP) to discuss policy options that encourage interstate licensure among behavioral health providers.
ASPE Issue Brief, Report

Evaluation of the Assisted Outpatient Treatment Grant Program for Individuals with Serious Mental Illness

Assisted outpatient treatment (AOT) is a civil court procedure whereby a judge orders an adult with serious mental illness (SMI) to comply with community-based treatment. Developed as a less restrictive alternative to involuntary hospitalization, AOT focuses on individuals at risk of clinical deterioration or rehospitalization because they do not voluntarily comply with prescribed treatment.